Missouri Senate Bill SB45

Missouri 2025 Regular Session

• Introduced: 1/8/25
• Refer: 1/16/25

Caption

Enacts provisions relating to payments for prescription drugs

Impact

The implementation of SB 45 is expected to have significant implications on state laws concerning pharmacy operations and patient access to medications. By mandating transparency in reimbursement processes and allowing for a systematic appeal process for disputes regarding maximum allowable cost pricing, the bill enhances the protection of both pharmacies and patients. Patients will benefit from potentially lower prescription costs as pharmacies will be incentivized to remain competitive in pricing while ensuring profitability. This bill effectively places a check on the practices of PBMs that may have previously favored certain pharmaceutical manufacturers over others.

Summary

Senate Bill 45 aims to reform the regulations surrounding pharmacy benefits managers (PBMs) and their interactions with pharmacies in the state of Missouri. The bill introduces new provisions that mandate PBMs to provide clear pricing structures, ensuring that pharmacies are not reimbursed less than their actual costs for dispensing prescription drugs. A critical aspect of the bill is the requirement for PBMs to update maximum allowable cost pricing for prescription drugs regularly, specifically at least every seven days, thereby reflecting market conditions more accurately. This requirement is designed to ensure fair reimbursement rates for pharmacies, promoting stability in the pharmaceutical supply chain.

Contention

While supporters of SB 45 argue that it is a step towards a fairer and more transparent healthcare system, there are points of contention among stakeholders. Some pharmacy benefits managers have expressed concerns that the regulatory burden imposed by the bill could lead to higher operating costs, which might ultimately be passed on to consumers. Additionally, there are apprehensions about the potential impacts on the competitive landscape of pharmacy operations, as smaller pharmacies may find it challenging to absorb the costs associated with compliance. Thus, while the bill aims to improve transparency and fairness, it also raises questions about its broader economic implications for the pharmacy sector.